LIFE:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund Hedged Units (CAD)

COMMON STOCK | |

Last Closing

CAD 21.26

Change

0.00 (0.00)%

Market Cap

CAD 0.01B

Volume

4.81K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-08 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TD-PFB:CA Toronto Dominion Bank Pref B

-0.10 (-0.41%)

CAD 195.27B
TD-PFD:CA Toronto Dominion Bank Pref D

-0.05 (-0.21%)

CAD 162.58B
TD-PFI:CA Toronto-Dominion Bank Pref Ser..

+0.15 (+0.59%)

CAD 160.00B
TD-PFM:CA Toronto-Dominion Bank Pref Ser..

+0.01 (+0.04%)

CAD 141.82B
ENB-PFA:CA Enbridge Inc Pref 9

-0.11 (-0.60%)

CAD 111.14B
ENB-PFV:CA Enbridge Inc Pref 5

+0.15 (+0.68%)

CAD 110.48B
ENB-PFC:CA Enbridge Inc Pref 11

-0.08 (-0.46%)

CAD 105.63B
ENB-PFG:CA Enbridge Inc Pref 15

N/A

CAD 100.73B
ENB-PFU:CA Enbridge Inc Pref L

+0.19 (+0.91%)

CAD 81.76B
PPL-PFA:CA Pembina Pipeline Corp Pref Ser..

-0.25 (-1.10%)

CAD 9.28B

ETFs Containing LIFE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.26% N/A N/A 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.26% N/A N/A 34% F
Trailing 12 Months  
Capital Gain -2.39% N/A N/A 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.39% N/A N/A 23% F
Trailing 5 Years  
Capital Gain 14.30% N/A N/A 50% F
Dividend Return 6.32% N/A N/A 27% F
Total Return 20.62% N/A N/A 46% F
Average Annual (5 Year Horizon)  
Capital Gain 1.58% N/A N/A 49% F
Dividend Return 2.73% N/A N/A 48% F
Total Return 1.15% N/A N/A 38% F
Risk Return Profile  
Volatility (Standard Deviation) 7.37% N/A N/A 77% C+
Risk Adjusted Return 37.11% N/A N/A 63% D
Market Capitalization 0.01B N/A N/A 9% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike